Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942298 | 1.00 | HMGCR (0.46) | HMGCRGABRA1GABRB2APPHTR1D | |
| SCHEMBL348572 | 0.84 | GABRA1 (0.40) | HMGCRGABRA1GABRB2HTR1DPOLB | |
| SCHEMBL478280 | 0.84 | GABRA1 (0.46) | HMGCRGABRA1GABRB2HTR1DPOLB | |
| SCHEMBL18740304 | 0.79 | IDO1 (0.39) | HMGCR | |
| SCHEMBL4391448 | 0.77 | TACR1 (0.43) | HMGCRGABRA1GABRB2HTR1DPOLB | |
| SCHEMBL9922034 | 0.77 | GABRA1 (0.52) | HMGCRGABRA1GABRB2APPHTR1D | |
| SCHEMBL26982475 | 0.77 | TRPA1 (0.36) | — | |
| SCHEMBL5666262 | 0.77 | GABRA1 (0.46) | HMGCRGABRA1GABRB2APPHTR1D | |
| SCHEMBL15574021 | 0.77 | TRPA1 (0.36) | — | |
| SCHEMBL13208365 | 0.75 | GABRA1 (0.33) | HMGCRGABRA1GABRB2HTR1DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| EP-4384165-B1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-09 | — | — | EP | disclosed |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| EP-4384165-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | Janssen Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076351-A | Monoacylglycerol lipase modulators for autism spectrum disorders | 詹森药业有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-07 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| WO-2023019094-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | disclosed |
| CN-115066422-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021160602-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | WO | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | ELI LILLY AND COMPANY | 2014-09-18 | — | — | US | disclosed |
| WO-2013066640-A1 | SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2013-05-10 | — | — | WO | disclosed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | HMGCR 608/4885GABRA1 821/4885GABRB2 282/4885 |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | HMGCR 1348/4885GABRA1 1227/4885GABRB2 1458/4885 |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | HMGCR 391/4885GABRA1 393/4885GABRB2 175/4885 |
| US-20240299365-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | HMGCR 391/4885GABRA1 393/4885GABRB2 175/4885 |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | HMGCR 608/4885GABRA1 821/4885GABRB2 282/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | HMGCR 391/4885GABRA1 393/4885GABRB2 175/4885 |
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | RARB, RARA, RARG | HMGCR 3734/4885GABRA1 179/4885GABRB2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.